Trends in Pharmacological Sciences
OpinionRationale, pharmacology and clinical efficacy of partial agonists of α4β2 nACh receptors for smoking cessation
Section snippets
Smoking and tobacco addiction
Despite broad awareness of the health risks to individuals, tobacco smoking is the leading cause of preventable mortality in industrialized countries [1]. Globally, tobacco-attributable mortality is projected to increase to 6.4 million per annum in 2015, and account for 10% of all deaths [2]. Currently available treatments for nicotine addiction, including nicotine replacement therapy (NRT) and bupropion (Zyban®), only double the placebo quit rate in clinical trials 3, 4, highlighting the unmet
Role of α4β2 nAChRs in nicotine dependence
Recent insights into the molecular mechanisms that underlie nicotine dependence have revealed unique opportunities for developing more-efficacious treatments for tobacco addiction. Upon smoking, inhaled nicotine enters the brain within seconds, reaching maximal concentrations within 2 min 14, 15, and acts on nAChRs located on DA and GABA neurons in the mesolimbic system in the ventral tegmental area (VTA) (Figure 1). Nicotine can both activate and desensitize these receptors, depending on the
Why α4β2 nAChR partial agonists for smoking cessation?
Given the central role of α4β2 nAChRs in the reinforcement and maintenance of nicotine dependence, modulating the activity of these receptors would be expected to have therapeutic benefits. Specifically, partial agonists of α4β2 nAChRs that enhance the activity of these receptors sufficiently to blunt craving and withdrawal, but without associated abuse potential, are attractive options. Furthermore, high-affinity partial agonists of α4β2 nAChRs would have the additional potential benefit of
Agonist and antagonist combinations: a proof of concept for partial agonists
Rational approaches to pharmacotherapy for nicotine addiction would include direct activation of α4β2 nAChRs with an agonist to reduce craving and withdrawal symptoms when quitting, or blockade of α4β2 nAChRs with an antagonist to reduce reinforcement and reward from smoking. The first approach, represented by nicotine replacement therapy (NRT), uses nicotine as an agonist in safe delivery forms by eliminating the smoke that causes tobacco-related illnesses. NRT is effective [3] at reducing
Design of α4β2 nAChR partial agonists: clues from nature
Cytisine (Figure 3), which is a plant alkaloid that has been used for >40 years in Eastern Europe as a smoking cessation agent (see later), provided early support for the partial agonist theory. In 1994, evidence revealed cytisine to be a partial agonist of nAChRs [30], providing a rationale for its reported efficacy. Direct chemical modifications of cytisine did not lead to viable drug candidates (Figure 3). Although entirely synthetic variations of the cytisine [3.3.1]-bicyclic framework
The discovery and neuropharmacology of α4β2 nAChR partial agonists
Although the pharmacological characteristics of partial agonists are easily formulated, the actual identification of a partial agonist with the desired profile presents a formidable challenge. The characterization of nAChR partial agonists became more practical only in the 1990s, with the application of functional in vitro assays – most notably patch clamp and fluorescence imaging plate reader (FLIPR) methodology – to ion channels expressed in oocytes or mammalian cell lines. This enabled the
Clinical efficacy: do partial agonists of α4β2 nAChRs work?
As noted, the potential benefits of dual agonist and antagonist action, as proposed by Rose and Levin [28], were originally examined by simultaneous nAChR agonist (NRT) and antagonist (mecamylamine) administration 38, 39. Two small studies showed that mecamylamine augmented the efficacy of NRT; however, there are no published data from larger studies confirming these results, and the combination has not yet become an established treatment for smoking cessation [29]. Interestingly, the
Concluding remarks
Treatment of tobacco addiction with partial agonists of α4β2 nAChRs offers a novel and well-validated pharmacotherapeutic approach. Mechanistically, these agents target the receptors that are believed to mediate the reinforcing effects of nicotine and, to some extent, mimic the agonist effects of nicotine sufficiently to reduce craving when quitting. Furthermore, partial agonists with sufficiently high receptor-binding affinity and free concentration in the brain will act as antagonists in the
Disclosure statement
Varenicline is a product of Pfizer and is marketed as CHANTIX™ (USA) and CHAMPIX™ (Europe and elsewhere). H.R., J.W.C., L.K.C., R.S.H. and K.E.W. are employees of Pfizer and own Pfizer stock. S.M.S. has received grants from and is a consultant for several pharmaceutical companies, including Pfizer, for which he is on the speakers’ bureau.
References (60)
- et al.
The neurobiology of tobacco addiction
Trends Pharmacol. Sci.
(1991) Arterial nicotine kinetics during cigarette smoking and intravenous nicotine administration: implications for addiction
Drug Alcohol Depend.
(1999)Self-administered nicotine activates the mesolimbic dopamine system through the ventral tegmental area
Brain Res.
(1994)Mecamylamine increases nicotine preference and attenuates nicotine discrimination
Pharmacol. Biochem. Behav.
(1989)3,5-Bicyclic aryl piperidines: a novel class of α4β2 neuronal nicotinic receptor partial agonists for smoking cessation
Bioorg. Med. Chem. Lett.
(2005)In pursuit of α4β2 nicotinic receptor partial agonists for smoking cessation: carbon analogs of (−)-cytisine
Bioorg. Med. Chem. Lett.
(2005)Pharmacological profile of the α4β2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid
Neuropharmacology
(2007)On the nature of allosteric transitions: a plausible model
J. Mol. Biol.
(1965)On the application of ‘a plausible model’ of allosteric proteins to the receptor for acetylcholine
J. Theor. Biol.
(1967)- et al.
Nicotine addiction: the possible role of functional upregulation
Trends Pharmacol. Sci.
(2002)
Non-nicotinic neuropharmacological strategies for nicotine dependence: beyond bupropion
Drug Disc. Today
WHO framework convention on tobacco control: a global ‘good’ for public health
Bull. World Health Organ.
Projections of global mortality and burden of disease from 2002 to 2030
PLoS Med.
Nicotine replacement therapy for smoking cessation
Cochrane Database of Systematic Reviews
Antidepressants for smoking cessation
Cochrane Database of Systemic Reviews
New treatments for smoking cessation
Cancer J. Clin.
The clinical significance of ‘small’ effects of smoking cessation treatments
Addiction
Extinguishing the rewarding value of smoke cues: pharmacological and behavioral treatments
Nic. Tobacco Res.
Control of the reinforcing effects of nicotine by associated environmental stimuli in animals and humans
Trends Pharmacol. Sci.
The neurobiology of tobacco dependence: a clinical perspective on the role of dopamine projections to the nucleus
Nic. Tobacco Res.
The neurobiology of nicotine addiction: bridging the gap from molecules to behaviour
Nat. Rev. Neurosci.
Nicotine addiction and comorbidity with alcohol abuse and mental illness
Nat. Neurosci.
Nicotinic modulation of neuronal networks: from receptors to cognition
Psychopharmacology (Berl.)
Nicotine absorption and cardiovascular effects with smokeless tobacco use: comparison with cigarettes and nicotine gum
Clin. Pharmacol. Ther.
Effects of nicotine on the nucleus accumbens and similarity of those of addictive drugs
Nature
Nicotinic cholinergic synaptic mechanisms in the ventral tegmental area contribute to nicotine addiction
Learn. Mem.
Subunit composition of functional nicotinic receptors in dopaminergic neurons investigated with knock-out mice
J. Neurosci.
acetylcholine receptors containing the β2 subunit are involved in the reinforcing properties of nicotine
Nature
Effects of nicotine in the dopaminergic system of mice lacking the α4 subunit of neuronal nicotinic acetylcholine receptors
Eur. J. Neurosci.
Nicotine reinforcement and cognition restored by targeted expression of nicotinic receptors
Nature
Cited by (211)
Quinoxaline: A comprehension of current pharmacological advancement in medicinal chemistry
2022, European Journal of Medicinal Chemistry ReportsVarenicline as a treatment for cannabis use disorder: A placebo-controlled pilot trial
2021, Drug and Alcohol DependenceCytisine and cytisine derivatives. More than smoking cessation aids
2021, Pharmacological Research5-HT<inf>2A</inf> and 5-HT<inf>2C</inf> receptors as potential targets for the treatment of nicotine use and dependence
2021, Progress in Brain Research